Press releases from Tavros Therapeutics

Read the latest news from Tavros Therapeutics.

Agreement includes the discovery and enhancement of targeted oncology drug targets and biomarkers, in addition to positioning existing compounds
Multi-target collaboration leverages Tavros’ proprietary functional genomic discovery program and OpenBench’s screening platform
Funds to be used to continue developing proprietary platform to rapidly identify synthetically lethal interactions to improve cancer care
DURHAM – Tavros Therapeutics, an emerging biotechnology company based out of Durham, has raised nearly $1 million in equity, according to a recent securities filing, and is working to discover “a new frontier” in oncology therapy.
A Duke University spin-out focused on cancer treatment is getting financial backing from a Raleigh-based investment fund.
NEW YORK, SAN DIEGO and DURHAM, N.C., May 28, 2020 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL) and Tavros Therapeutics, Inc., today announced a strategic collaboration to apply Tavros’ functional genomic discovery platform to develop next generation targeted small molecule drug candidates, initially to expand Zentalis’ oncology pipeline.

For media inquiries, contact